Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects

Keyphrases

• Adverse Effects 100%
• Pregnant Women 100%
• Interaction Effect 100%
• Pharmacogenetics 100%
• Selective Serotonin Reuptake Inhibitors 100%
• Drug Interactions 100%
• Congenital Anomalies 25%
• Neurodevelopmental Outcome 25%
• Severe Maternal 12%
• Maternal Infection 12%
• Autism Spectrum Disorder 12%
• Maternal Depression 12%
• Perinatal Outcome 12%
• Low Birth Weight 12%
• Prematurity 12%
• Should Be Given 12%
• Negative Effects 12%
• Cognitive Impairment 12%
• Expert Opinion 12%
• Area Cover 12%
• Cardiac Malformation 12%
• Child Development 12%
• Behavior Change 12%
• Event Outcomes 12%
• Serotonin-norepinephrine Reuptake Inhibitors 12%
• Neurodevelopmental 12%
• Treatment Discontinuation 12%
• Cytochrome P450 Enzymes 12%
• Persistent Pulmonary Hypertension of the Newborn 12%
• Minimal Effective Dose 12%
• Pharmacokinetic Differences 12%
• Gross Motor Delay 12%
• Language Ability 12%
• Neonatal Adaptation 12%
• Adaptive Challenges 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacogenetics 100%
• Selective Serotonin Reuptake Inhibitor 100%
• Drug-Drug Interaction 100%
• Congenital Malformation 42%
• Autism 14%
• Maternal Disease 14%
• Prematurity 14%
• Postnatal Depression 14%
• Cytochrome P450 14%
• Low Birth Weight 14%
• Cognitive Defect 14%
• Serotonin-Norepinephrine Reuptake Inhibitor 14%
• Persistent Pulmonary Hypertension 14%
• Pharmacokinetics 14%
• Minimal Effective Dose 14%